SETTLEMENT AGREEMENTSettlement Agreement • August 7th, 2018 • Catalyst Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS SETTLEMENT AGREEMENT (“Agreement”) is effective as of July 26, 2018 (the “Effective Date”) by and among, (i) Aceras BioMedical LLC, a Delaware limited liability company (“Aceras”), in its capacity as Stockholder Representative for the former stockholders (the “Stockholders”) of Huxley Pharmaceuticals, Inc., a Delaware corporation (“Huxley”), that are a party to the SPA (as such term is defined below), (ii) BioMarin Pharmaceutical Inc., a Delaware corporation (“BioMarin”), and (iii) Catalyst Pharmaceuticals, Inc. (f/k/a Catalyst Pharmaceutical Partners, Inc.), a Delaware corporation (“Catalyst”). Aceras, BioMarin, and Catalyst may be individually referred to herein as a “Party” and collectively referred to herein as the “Parties”.
